• RedHill Biopharma announced results from two laboratory studies confirming its Crohn's disease candidate RHB-204 killed MAP bacteria comparably to RHB-104.
• Comparable activity at lower doses of two active ingredients suggests potential for reduced toxicity and side effects.
• RHB-104 previously demonstrated improved efficacy over standard care alone in a positive Phase 3 Crohn's disease trial.
• RHB-204 is ready for Phase 2 development; partnerships are being pursued to advance the program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611020700PR_NEWS_USPR_____IO86565) on November 02, 2026, and is solely responsible for the information contained therein.